Ocular Therapeutix Stock Price, News & Analysis (NASDAQ:OCUL)

$4.15 -0.03 (-0.72 %)
(As of 11/24/2017 02:34 AM ET)
Previous Close$4.18
Today's Range$4.12 - $4.27
52-Week Range$4.11 - $11.91
Volume235,027 shs
Average Volume873,963 shs
Market Capitalization$123.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000

Debt

Debt-to-Equity Ratio0.39%
Current Ratio4.79%
Quick Ratio4.78%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.89 million
Price / Sales64.64
Cash FlowN/A
Price / CashN/A
Book Value$1.22 per share
Price / Book3.40

Profitability

Trailing EPS($2.28)
Net Income$-44,700,000.00
Net Margins-3,241.19%
Return on Equity-126.31%
Return on Assets-81.51%

Miscellaneous

Employees118
Outstanding Shares29,440,000

Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.54). The biopharmaceutical company had revenue of $523 million for the quarter, compared to analysts' expectations of $0.52 million. Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The firm's revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.39) earnings per share. View Ocular Therapeutix's Earnings History.

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?

6 Wall Street analysts have issued 1 year price objectives for Ocular Therapeutix's shares. Their forecasts range from $8.00 to $60.00. On average, they anticipate Ocular Therapeutix's stock price to reach $20.67 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.

What are Wall Street analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (11/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Presentation at our conference emphasized added biopharma leadership experience to a previously medical technology-focused company." (9/25/2017)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:

  • Amarpreet Sawhney Ph.D., Executive Chairman of the Board (Age 50)
  • Antony Charles Mattessich, President, Chief Executive Officer (Age 50)
  • Donald D. Notman Jr., Chief Financial Officer
  • James Fortune, Chief Operating Officer (Age 58)
  • Daniel M. Bollag Ph.D., Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality (Age 56)
  • Michael H. Goldstein M.D., Chief Medical Officer (Age 50)
  • Jaswinder S. Chadha, Director (Age 49)
  • W. James O'Shea, Director (Age 67)
  • Jeffrey S. Heier M.D., Independent Director (Age 56)
  • Richard L. Lindstrom M.D., Independent Director (Age 69)

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (6.80%), Columbus Circle Investors (3.69%), Deltec Asset Management LLC (1.07%) and Dimensional Fund Advisors LP (0.13%). View Institutional Ownership Trends for Ocular Therapeutix.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC and Jennison Associates LLC. View Insider Buying and Selling for Ocular Therapeutix.

Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?

Ocular Therapeutix's stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors and Dimensional Fund Advisors LP. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of Ocular Therapeutix stock can currently be purchased for approximately $4.15.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $123.05 million and generates $1.89 million in revenue each year. The biopharmaceutical company earns $-44,700,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Ocular Therapeutix employs 118 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]


MarketBeat Community Rating for Ocular Therapeutix (OCUL)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ocular Therapeutix (NASDAQ:OCUL)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.302.202.502.83
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.23$20.23$21.41$26.97
Price Target Upside: 276.72% upside242.88% upside270.34% upside179.81% upside

Consensus Price Target History for Ocular Therapeutix (NASDAQ:OCUL)

Price Target History for Ocular Therapeutix (NASDAQ:OCUL)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$12.00N/AView Rating Details
9/25/2017Cantor FitzgeraldReiterated RatingBuy$21.00LowView Rating Details
8/10/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 -> $8.00LowView Rating Details
3/13/2017Cowen IncReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank Of CanadaReiterated RatingOutperform$30.00 -> $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Ocular Therapeutix (NASDAQ:OCUL)

Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)($0.54)$0.52 million$523.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.59)($0.64)$0.51 million$0.40 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.48)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-2.37 EPS
Next Year EPS Consensus Estimate: $-2.22 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ OCUL)

Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 53.97%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Insider Trades by Quarter for Ocular Therapeutix (NASDAQ OCUL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Amarpreet SawhneyChairmanBuy19,000$5.18$98,420.00View SEC Filing  
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocular Therapeutix (NASDAQ OCUL)

Source:
DateHeadline
Insider Buying: Ocular Therapeutix, Inc. (OCUL) Chairman Acquires 19,000 Shares of StockInsider Buying: Ocular Therapeutix, Inc. (OCUL) Chairman Acquires 19,000 Shares of Stock
www.americanbankingnews.com - November 20 at 10:50 AM
Ocular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by AnalystsOcular Therapeutix, Inc. (OCUL) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:38 AM
Ocular Therapeutix, Inc. (OCUL) Upgraded to "Hold" at Zacks Investment ResearchOcular Therapeutix, Inc. (OCUL) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Edited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of OCUL earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 8:00 AM
Ocular Therapeutix, Inc. (OCUL) Given Buy Rating at HC WainwrightOcular Therapeutix, Inc. (OCUL) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
Critical Contrast: Ocular Therapeutix (OCUL) & Its PeersCritical Contrast: Ocular Therapeutix (OCUL) & Its Peers
www.americanbankingnews.com - November 8 at 2:08 PM
Ocular Therapeutix, Inc. (OCUL) Issues Quarterly  Earnings ResultsOcular Therapeutix, Inc. (OCUL) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Ocular Therapeutix Inc to Host Earnings CallOcular Therapeutix Inc to Host Earnings Call
finance.yahoo.com - November 7 at 4:40 PM
Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateOcular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 4:40 PM
Ocular Therapeutix (OCUL) vs. MiMedx Group (MDXG) Critical ContrastOcular Therapeutix (OCUL) vs. MiMedx Group (MDXG) Critical Contrast
www.americanbankingnews.com - November 7 at 2:06 PM
Head-To-Head Comparison: Ocular Therapeutix (OCUL) & Its PeersHead-To-Head Comparison: Ocular Therapeutix (OCUL) & Its Peers
www.americanbankingnews.com - November 4 at 10:12 AM
Ocular Therapeutix™ to Report Third Quarter 2017 Financial ResultsOcular Therapeutix™ to Report Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 7:12 AM
Ocular Therapeutix, Inc. (OCUL) Scheduled to Post Quarterly Earnings on TuesdayOcular Therapeutix, Inc. (OCUL) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:26 AM
Financial Review: Integra LifeSciences Holdings Corporation (IART) vs. Ocular Therapeutix (OCUL)Financial Review: Integra LifeSciences Holdings Corporation (IART) vs. Ocular Therapeutix (OCUL)
www.americanbankingnews.com - October 26 at 11:36 AM
Ocular Therapeutix (OCUL) versus Its Peers Head to Head ComparisonOcular Therapeutix (OCUL) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - October 23 at 6:28 PM
Ocular Therapeutix, Inc. (OCUL) Coverage Initiated by Analysts at GuggenheimOcular Therapeutix, Inc. (OCUL) Coverage Initiated by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:20 PM
Ocular Therapeutix, Inc. (OCUL) Receives Consensus Recommendation of "Hold" from AnalystsOcular Therapeutix, Inc. (OCUL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 4:42 AM
Ocular Therapeutix Is Now Oversold (OCUL)Ocular Therapeutix Is Now Oversold (OCUL)
www.thestreet.com - October 20 at 7:05 AM
Ocular Therapeutix™ Appoints Donald Notman as Chief Financial OfficerOcular Therapeutix™ Appoints Donald Notman as Chief Financial Officer
finance.yahoo.com - October 2 at 7:52 PM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of ShareholdersRobbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders
finance.yahoo.com - October 2 at 7:52 PM
How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio?How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio?
finance.yahoo.com - October 2 at 7:52 PM
Financial Review: NuVasive (NUVA) vs. Ocular Therapeutix (OCUL)Financial Review: NuVasive (NUVA) vs. Ocular Therapeutix (OCUL)
www.americanbankingnews.com - October 1 at 8:24 AM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of ... - Business Wire (press release)Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of ... - Business Wire (press release)
www.businesswire.com - September 28 at 7:19 PM
Ocular Therapeutix, Inc. (OCUL) Receives Average Rating of "Hold" from AnalystsOcular Therapeutix, Inc. (OCUL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 27 at 4:42 AM
Inogen (INGN) versus Ocular Therapeutix (OCUL) Financial ReviewInogen (INGN) versus Ocular Therapeutix (OCUL) Financial Review
www.americanbankingnews.com - September 26 at 10:10 PM
Ocular Therapeutixs (OCUL) "Buy" Rating Reaffirmed at Cantor FitzgeraldOcular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 9:14 PM
Head-To-Head Comparison: K2M Group Holdings (KTWO) and Ocular Therapeutix (OCUL)Head-To-Head Comparison: K2M Group Holdings (KTWO) and Ocular Therapeutix (OCUL)
www.americanbankingnews.com - September 19 at 2:30 PM
Ocular Therapeutix (OCUL) vs. Steris Plc (STE) Financial SurveyOcular Therapeutix (OCUL) vs. Steris Plc (STE) Financial Survey
www.americanbankingnews.com - September 15 at 2:30 PM
Have Investors Already Priced In Ocular Therapeutix Inc’s (OCUL) Growth?Have Investors Already Priced In Ocular Therapeutix Inc’s (OCUL) Growth?
finance.yahoo.com - September 14 at 8:40 AM
Ocular Therapeutix (OCUL) Appoints Michael Goldstein as CMO - StreetInsider.comOcular Therapeutix (OCUL) Appoints Michael Goldstein as CMO - StreetInsider.com
www.streetinsider.com - September 10 at 5:35 AM
Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical OfficerOcular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
finance.yahoo.com - September 9 at 6:58 AM
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences - Business Wire (press release)Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences - Business Wire (press release)
www.businesswire.com - September 7 at 7:10 AM
Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesOcular Therapeutix™ to Present at Three Upcoming Investor Conferences
finance.yahoo.com - September 7 at 7:10 AM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 6 at 7:10 AM
OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - September 6 at 7:10 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 2 at 7:01 AM
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCULUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - September 2 at 7:01 AM
DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ocular Therapeutix, Inc. (Nasdaq:OCUL) To Contact The FirmDEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ocular Therapeutix, Inc. (Nasdaq:OCUL) To Contact The Firm
finance.yahoo.com - September 2 at 7:01 AM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - September 2 at 7:01 AM
DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
finance.yahoo.com - September 2 at 7:01 AM
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 2 at 7:01 AM
5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc ... - GlobeNewswire (press release)5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc ... - GlobeNewswire (press release)
globenewswire.com - September 1 at 6:40 AM
5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 1 at 6:40 AM
OCUL EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017OCUL EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
finance.yahoo.com - August 31 at 8:12 AM
SEPTEMBER 5 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the FirmSEPTEMBER 5 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - August 31 at 8:11 AM
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix, Inc. (OCUL) and Encourages Investors with Losses to Contact the Firm Before September 5, 2017Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix, Inc. (OCUL) and Encourages Investors with Losses to Contact the Firm Before September 5, 2017
finance.yahoo.com - August 29 at 6:15 AM
DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - August 28 at 3:49 PM
Research Analysts Offer Predictions for Ocular Therapeutix Incs FY2017 Earnings (OCUL)Research Analysts Offer Predictions for Ocular Therapeutix Inc's FY2017 Earnings (OCUL)
www.americanbankingnews.com - August 28 at 2:52 AM
Bernstein Liebhard LLP Announces That Only 10 Days Remain To File A Motion For Lead Plaintiff In A Class Action ... - PR Newswire (press release)Bernstein Liebhard LLP Announces That Only 10 Days Remain To File A Motion For Lead Plaintiff In A Class Action ... - PR Newswire (press release)
www.prnewswire.com - August 27 at 4:16 AM
Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocular Therapeutix, Inc. - Business Wire (press release)Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocular Therapeutix, Inc. - Business Wire (press release)
www.businesswire.com - August 26 at 7:58 AM

Social Media

Financials

Chart

Ocular Therapeutix (NASDAQ OCUL) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.